Search Results for: IT-27

TOOLS FOR SELECTIVELY ALTERING CELLS BASED ON CELL-SURFACE MARKERS You’re still publishing and we’re still open to meet your targeting needs.  You can place your orders online or contact us. Stay safe and healthy!Denise Higginswww.ATSbio.com SERVICES FOR SELECTIVELY ALTERING AND ASSAYING CELLS Restricted access can slow or halt your research and drug development activities.  We […]

IT-01: 192-IgG-SAP     • Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson’s disease. LID – 10.1007/s00213-018-5150-y [doi]. Koshy Cherian A et al. (2019). Psychopharmacol (Berl), [Epub ahead of print]  Dose: Basal forebrain cholinergic neurons situated in the nucleus basalis and substantia innominata were targeted with

Enhanced Targeting of Triple-Negative Breast Carcinoma and Malignant Melanoma by Photochemical Internalization of CSPG4-Targeting Immunotoxins. Eng MS, Kaur J, Prasmickaite L, Engesaeter BO, Weyergang A, Skarpen E, Berg K, Rosenblum MG, Maelandsmo GM, Hogset A, Ferrone S, & Selbo PK. (2018). Photochemical & Photobiological Sciences 17(5):539-551. Conclusion: The combination of the drug delivery technology PCI

Aptamers are small, synthetic, single-stranded nucleic acids that fold into unique secondary structures. Unlike peptides and monoclonal antibodies, they are essentially non-immunogenic even when administered in excess amounts. The publications below explain how biotinylated aptamers combined with Streptavidin-conjugated saporin (Streptavidin-ZAP) can be used to screen aptamers for their ability to internalize into a specific cell

2018 starts off with 3 new publications using ATS products. Check out these articles and take advantage of special promotions for each of the products used. Melanopsin Retinal Ganglion Cells Are Not Labeled in Thy-1yfp-16 Transgenic Mice. Grillo, SL, & Stella, SL, Jr. (2018). Neuroreport, 29 (2):118-122. 2017/12/19. Objective: to determine whether mRGCs are labeled

Gene therapy has been proposed for a variety of genetic disorders, including severe combined immunodeficiency, but it has not yet found routine use in the clinic, in part because of potential complications. To help pave the way for safer translation of such gene therapy, Schiroli et al. studied potential approaches to gene therapy in mouse